112 related articles for article (PubMed ID: 20435573)
1. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
De Portu S; Mantovani LG; Ravaioli A; Tamburini E; Bollina R; Cozzi C; Grimaldi AM; Testa TE; Bianchessi C; Carteni G
J Chemother; 2010 Apr; 22(2):125-8. PubMed ID: 20435573
[TBL] [Abstract][Full Text] [Related]
2. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Chu E; Shi N; Wei W; Bendell JC; Cartwright T
Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
[TBL] [Abstract][Full Text] [Related]
4. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Best JH; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
[TBL] [Abstract][Full Text] [Related]
7. [Economic evaluation of capecitabine use as first line treatment in patients with advanced gastric carcinoma in Portugal].
Macedo A; Pereira C; Gonçalves J; Sousa C
Acta Med Port; 2009; 22(6):827-32. PubMed ID: 20350467
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
9. Cost comparison of capecitabine in patients with breast cancer.
Rugo HS; Kohles J; Schulman KL
Am J Clin Oncol; 2010 Dec; 33(6):550-6. PubMed ID: 20051811
[TBL] [Abstract][Full Text] [Related]
10. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
Chu E; Schulman KL; Zelt S; Song X
Cancer; 2009 Apr; 115(7):1412-23. PubMed ID: 19195048
[TBL] [Abstract][Full Text] [Related]
11. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
Lopatriello S; Amoroso D; Donati S; Alabiso O; Forti L; Fornasiero A; Smergo A; Lalli A; Iacono C; Lucenti A; D'Alonzo L; Negrini C
Eur J Cancer; 2008 Nov; 44(17):2615-22. PubMed ID: 18805000
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Chu E; Cartwright TH
J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
[No Abstract] [Full Text] [Related]
13. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
Drugs; 2008; 68(7):949-61. PubMed ID: 18457461
[TBL] [Abstract][Full Text] [Related]
15. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
16. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
17. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Cassidy J; Schmoll HJ; Van Cutsem E
J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
[No Abstract] [Full Text] [Related]
18. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
[TBL] [Abstract][Full Text] [Related]
19. Costs of treatment of colorectal cancer in different settings in Germany.
Hieke K; Kleeberg UR; Stauch M; Grothey A
Eur J Health Econ; 2004 Oct; 5(3):270-3. PubMed ID: 15714348
[TBL] [Abstract][Full Text] [Related]
20. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
